News

The financing will be used to further develop a migraine compound, COL-144, and to advance a preclinical pipeline of novel chemical entities targeting neurological and psychiatric disorders. The

The therapeutic candidate is expected to enter Phase I clinical testing in the third quarter of 2008. The total transaction is valued at $90 million upfront with a

Under the terms of the agreement, PainReform will obtain exclusive North American rights to ETI-211 and will also obtain an option to expand the agreement to other countries

Novartis disputes the State of Alabama’s claims that the prices provided by Novartis Pharmaceuticals (NPC) to reporting services resulted in overpayment to pharmacists and doctors in the Alabama

MiddleBrook has entered into a definitive securities purchase agreement with Equity Group Investments (EGI) for the sale of 30.30 million shares of its common stock at $3.30 per

The investment will allow Ibis to further develop the Ibis T5000 Biosensor System, which reportedly offers a unique solution for rapid identification and characterization of infectious agents. By

Dr LeBel has served on Akesis’s board of directors since December 2007. The company also stated that current president, Jay Lichter will retain the position of CEO and

Adam Singer, chairman and CEO of IPC, said: “The acquisition of Texas Inpatient Services (TIPS) continues to strengthen IPC’s position in this important market and sets the stage

Provista’s BT Test, a new blood test to aid healthcare providers in early breast cancer detection, will be provided through International Health Technology’s (IHT) women’s clinic for breast